Chimerix

Investors

Chimerix has received funding through a combination of non-dilutive government grants and private equity investments from leading venture capital firms, including Alta Partners, Asset Management Company, Canaan Partners, Frazier Healthcare Ventures, Morningside Group, New Leaf Venture Partners, Pappas Ventures and Sanderling Ventures.

Alta Partners

Alta Partners is a San Francisco-based venture capital firm focused on life sciences investing. Founded in 1996, the firm has raised $2 billion in committed capital through eight venture fund programs. Alta invests in life sciences companies across the development continuum, from company formation to later-stage opportunities, and has funded more than 130 companies in the sector to date.

Asset Management Company

Asset Management Company is a leading Silicon Valley venture capital firm and is one of the first venture capital firms founded on the West Coast of the United States. Since 1965, the company has invested in early-stage venture opportunities in the information technology and life sciences sectors. Asset Management's portfolio reflects the values of its partners and the entrepreneurs they finance: technological innovation, strategic vision, market focus and management expertise. Specializing in seed and early stage funding, Asset Management Company is a founding investor in Chimerix, Inc and Dr. Graham Crooke serves on Chimerix's Board of Directors.

Canaan Partners

Canaan Partners invests in visionary entrepreneurs and provides them the networks, insights and operational guidance required to build high-performance technology and healthcare companies.  Founded in 1987, the firm has raised eight funds and completed more than 77 acquisitions and 52 IPOs.  With $3 billion under management and a worldwide footprint, the firm’s healthcare team is committed to catalyzing the growth of biopharmaceutical, medical device and diagnostics companies that are revolutionizing the practice of medicine.  Among its successes are BiPar Sciences, pioneering PARP inhibitors for novel tumor-selective cancer therapies; Cerexa Inc., one of the largest biotech acquisitions of 2007; DexCom Inc., the largest diagnostics IPO of 2005; and Amicus Therapeutics, developing pharmacological chaperones to treat rare genetic diseases.  Other Canaan healthcare investments include Advanced BioHealing, Calibra Medical, Chimerix, Inc., Liquidia Technologies, Transcend Medical and VaxInnate.  Canaan has offices in California, Connecticut, India and Israel.

Frazier Healthcare Ventures

Founded in 1991, Frazier Healthcare Ventures is a leading provider of venture and growth equity capital to emerging biopharma, medical device and healthcare service companies. With over $1.8 billion under management, Frazier Healthcare has invested in over 100 companies across the entire development spectrum. From seed stage venture investments to leveraged recapitalizations of cash generating companies, Frazier Healthcare Ventures has established itself among entrepreneurs and seasoned executives as a preferred partner to create and grow successful healthcare companies.

Morningside Group

Morningside Group invests in private equity and venture capital opportunities in North America, Europe and Asia Pacific. Morningside Group has investments in the following sectors -- machinery manufacturing, high-tech, media, telecommunication, life science, education and cleantech. The group is managed by experienced investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate.

In addition to its investment activities, Morningside Group is deeply committed to being socially responsible. Providing access to educational opportunities and supporting scientific research are two major areas of focus for Morningside's philanthropic endeavors.

New Leaf Venture Partners

New Leaf Venture Partners is a leader in healthcare technology venture investing, whose investment professionals bring a unique blend of technological, clinical, and operational experience to its investments. New Leaf works closely with its entrepreneurs to help build successful portfolio companies; its objectives with each investment are to back a strong, entrepreneurial management team, to provide appropriate financial resources, to help build a great company, and to create exceptional equity value. The firm focuses primarily on biopharmaceutical products, medical devices, and diagnostics & laboratory infrastructure technologies. Founded in 2005 when the healthcare team spun out from the Sprout Group, the venture capital affiliate of Credit Suisse, the New Leaf team has invested in over 100 companies and currently manages $1.1 billion in assets.

Pappas Ventures

Founded in 1994, Pappas Ventures has more than $350 million in capital under management. We have guided the launch and/or development of some 50 life sciences companies, and to date a third of them have completed initial public offerings or successfully merged with corporate partners. Our scientific, medical and business professionals work closely with exceptional entrepreneurs to provide our portfolio companies with the financing, guidance and extensive network of relationships necessary to build successful enterprises.

Sanderling Ventures

Founded in 1979, Sanderling is among the oldest investment firms dedicated to biomedical investing. Sanderling’s unique approach combines a specialized investment focus with active management and long-term commitment. Since its inception, Sanderling has supported over 40 biomedical companies from very early stages through commercial development.